期刊文献+

toremifene增敏含铂方案治疗ⅢB、Ⅳ期NSCLC的临床Ⅱ期随机对照研究的初步结果 被引量:2

The preliminary results of a phase Ⅱ randomized clinical trial of high-dose toremifene chemosensitization in stage ⅢB/Ⅳ non-small cell lung cancer
下载PDF
导出
摘要 目的 在ⅢB、Ⅳ期非小细胞肺癌 (NSCLC)患者中 ,观察大剂量toremifene是否能够增加含铂联合化疗方案的疗效。方法 ⅢB、Ⅳ期初治NSCLC患者随机分成A、B两组 ,A组接受大剂量toremifene加铂类为基础的联合化疗方案 ,B组仅行以铂类为基础的联合化疗。结果 第 1次中期分析有 3 0例符合入选标准的患者入组 ,两组之间的血液毒性和非血液毒性均没有统计学差异。A组中位生存期为 8个月 ,95 %置信区间 (CI)为 6.63~ 9.3 7,B组中位生存期为 7.5个月 ,95 %CI为 4.75~ 10 .2 5 ,差异无统计学意义 (P =0 .9)。A组 1年生存率为 3 1% ,对照组 2 8% ,差异无统计学意义 (P =0 .87)。A组化疗有效率为 2 5 % ( 4 /16) ,对照组 2 1% ( 3 /14 ) ,差异无统计学意义 (P =0 .99)。结论 大剂量toremifene加含铂联合化疗方案治疗ⅢB、Ⅳ期NSCLC ,与单用含铂联合化疗方案比较 ,未能显示增加化疗疗效作用 。 Objective To investigate whether high dose toremifene can enhance the efficacy of chemotherapy in non small cell lung cancer. Methods Untreated stage ⅢB/Ⅳ non small cell lung cancer patients were randomly devided into group A (high dose toremifene combined with the platinum based chemotherapy) or group B (the same platinum based chemotherapy alone). Results A total of 30 eligible patients had been recruited. Hemotologic and nonhemotologic toxicities were similar with no statistic difference. The median survival for group A was 8 months, 95% CI (6.63 9.37) versus 7.5 months, 95% CI (4.75 10.25) for group B ( P =0.9). One year survival rate was 31% for group A versus 28% for group B ( P =0.87). The response rate was 25% for group A versus 21% for group B ( P =0.99).Conclusion The results suggest that high dose toremifene does not enhance the efficacy of platinum based chemotherapy for ⅢB/Ⅳ non small cell lung cancer but toxicities are well tolerated.
出处 《中国肺癌杂志》 CAS 2003年第5期335-338,共4页 Chinese Journal of Lung Cancer
关键词 治疗 NSCLC 非小细胞肺癌 toremliene 肿瘤 Toremifene Non small cell lung cancer Drug resistance Chemotherapy
  • 相关文献

参考文献1

  • 1方积乾主编.医学统计学与电脑试验[M].上海:上海科学技术出版社,1997.75.

同被引文献39

  • 1蔡莉,王滨,苍柏.托瑞米芬协同EP方案对耐药非小细胞肺癌的影响[J].实用肿瘤学杂志,2004,18(3):166-168. 被引量:3
  • 2周彩存,张捷,郑迪,吕梅君,鲁冰,徐建芳.托瑞米芬联合长春地辛和顺铂化疗方案治疗不能手术切除的非小细胞肺癌[J].中华结核和呼吸杂志,2004,27(8):546-548. 被引量:8
  • 3臧旺福,陈云富,孙秀威,鄢凤昌,冯占军.女性肺癌对雌、孕激素受体的依赖及受体与预后的关系─附57例临床病理研究[J].肿瘤防治研究,1994,21(2):76-78. 被引量:14
  • 4Di Nunno L, Larsson LG, Rinehart JJ, et al. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med,2000,124(10):1467-1470.
  • 5Mollerup S, Jorgensen K, Berge G, et al. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer,2002,37(2):153-159.
  • 6Bentzen SM, Skoczylas JZ, Overgaard M, et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst,1996,88(13):918-922.
  • 7van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet,1994,343(8895):448-452.
  • 8Millward MJ, Lien EA, Robinson A, et al. High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology,1994,51(1):79-83.
  • 9Perez EA, Gandara DR, Edelman MJ, et al. Phase Ⅰ trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest,2003,21(1):1-6.
  • 10Lara PN Jr, Gandara DR, Longmate J, et al. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase Ⅱ California Cancer Consortium Trial. Cancer Chemother Pharmacol,2001,48(1):22-28.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部